Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort.

Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; FHDH-ANRS CO4.

Int J Cancer. 2015 May 14. doi: 10.1002/ijc.29603. [Epub ahead of print]

PMID:
25976897
2.

Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.

Grabar S, Tattevin P, Selinger-Leneman H, de La Blanchardiere A, de Truchis P, Rabaud C, Rey D, Daneluzzi V, Ferret S, Lascaux AS, Hanslik T, Costagliola D, Launay O; French Hospital Database on HIV (FHDH-ANRS CO4 Cohort).

Clin Infect Dis. 2015 Apr 15;60(8):1269-77. doi: 10.1093/cid/ciu1161. Epub 2015 Jan 18.

PMID:
25601456
3.

Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access.

Delaugerre C, Ghosn J, Lacombe JM, Pialoux G, Cuzin L, Launay O, Menard A, de Truchis P, Costagliola D; FHDH-ANRS CO4.

Clin Infect Dis. 2015 Feb 1;60(3):463-72. doi: 10.1093/cid/ciu834. Epub 2014 Oct 23.

PMID:
25344539
4.

Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.

Hleyhel M, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4).

AIDS. 2014 Sep 10;28(14):2109-18. doi: 10.1097/QAD.0000000000000382.

PMID:
25265077
5.

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.

Potard V, Rey D, Poizot-Martin I, Mokhtari S, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; FHDH ANRS CO4 (French Hospital Database on HIV, Agence Nationale de Recherches sur le Sida, cohort 4).

J Int AIDS Soc. 2014 Sep 25;17:19070. doi: 10.7448/IAS.17.1.19070. eCollection 2014.

6.

Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort.

Jarzebowski W, Caumes E, Dupin N, Farhi D, Lascaux AS, Piketty C, de Truchis P, Bouldouyre MA, Derradji O, Pacanowski J, Costagliola D, Grabar S; FHDH-ANRS CO4 Study Team.

Arch Intern Med. 2012 Sep 10;172(16):1237-43.

PMID:
22826097
7.

Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.

Guiguet M, Ghosn J, Duvivier C, Meynard JL, Gras G, Partisani M, Teicher E, Mahamat A, Rodenbourg F, Launay O, Costagliola D; FHDH-ANRS CO4.

AIDS. 2012 Nov 28;26(18):2345-50. doi: 10.1097/QAD.0b013e32835646e0.

PMID:
22695301
8.

HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals.

Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, Boccara F, Costagliola D; French Hospital Database on HIV (FHDH)–ANRS CO4.

Clin Infect Dis. 2012 Aug;55(4):600-7. Epub 2012 May 18.

9.

Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.

Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, Mahamat A, Martinez V, Pradier C, Rouveix E, Simon A, Costagliola D, Abgrall S; FHDH-ANRS CO4.

J Antimicrob Chemother. 2011 Aug;66(8):1869-77. doi: 10.1093/jac/dkr208. Epub 2011 Jun 1.

10.

HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.

Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert JJ; FHDH-ANRS CO4.

Blood. 2011 Jul 7;118(1):44-9. doi: 10.1182/blood-2011-02-339275. Epub 2011 May 6.

11.

Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score.

Lanoy E, Guiguet M, Bentata M, Rouveix E, Dhiver C, Poizot-Martin I, Costagliola D, Gasnault J; FHDH-ANRS CO4.

Neurology. 2011 Feb 15;76(7):644-51. doi: 10.1212/WNL.0b013e31820c3089. Epub 2011 Jan 19.

PMID:
21248274
12.

IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.

Fontas E, Kousignian I, Pradier C, Poizot-Martin I, Durier C, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4; ANRS CO14.

J Antimicrob Chemother. 2010 Oct;65(10):2215-23. doi: 10.1093/jac/dkq296. Epub 2010 Aug 11.

13.

HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years.

Abgrall S, Del Giudice P, Melica G, Costagliola D; FHDH-ANRS CO4.

AIDS. 2010 Mar 13;24(5):763-71. doi: 10.1097/QAD.0b013e3283366747.

PMID:
20087155
14.

Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?

Kousignian I, Launay O, Mayaud C, Rabaud C, Costagliola D, Abgrall S; FHDH-ANRS CO4.

J Antimicrob Chemother. 2010 Jan;65(1):138-44. doi: 10.1093/jac/dkp402. Epub .

15.

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.

Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort.

Lancet Oncol. 2009 Dec;10(12):1152-9. doi: 10.1016/S1470-2045(09)70282-7. Epub 2009 Oct 7.

PMID:
19818686
16.

Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl.

Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S; FHDH-ANRS CO4 Clinical Epidemiology Group.

AIDS. 2009 Sep 24;23(15):1997-2004. doi: 10.1097/QAD.0b013e32832f4215.

PMID:
19654499
17.

CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3.

Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X; FHDH-ANRS CO4 Epidemiology Group.

Antivir Ther. 2009;14(3):451-7.

PMID:
19474479
18.

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.

Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups.

AIDS. 2009 Mar 27;23(6):717-24. doi: 10.1097/QAD.0b013e328326ca77.

PMID:
19279445
19.

Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.

Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):206-14. doi: 10.1097/QAI.0b013e318190018c.

PMID:
19131886
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk